Introduction: Adherence to disease-modifying therapies-key to optimizing outcomes in relapsing multiple sclerosis

Journal of Neuroscience Nursing

Volumn 42, Issue SUPPL.5, 2010, Pages

  Caon, Christina ^a   Saunders, Carol ^b   Smrtka, Jennifer ^a   Davis, Karolyn ^b   Davis, Alan ^b   Kay, Jonathan M ^b   Baxter, Nancy ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Ft Lauderdale MS Center ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT;

ADAPTIVE BEHAVIOR; CAREGIVER; FAMILY; HUMAN; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; REVIEW;

ADAPTATION, PSYCHOLOGICAL; ANTIRHEUMATIC AGENTS; CAREGIVERS; FAMILY; HUMANS; MEDICATION ADHERENCE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 78651421271     PISSN: 08880395     EISSN: None     Source Type: Journal    
DOI: 10.1097/JNN.0b013e3181ef82cd     Document Type: Review

References (10)

1. Avonex® (interferon beta-1a) [Package insert]. (2008). Cambridge, MA: Biogen Idec, Inc.
2. Betaseron® (interferon beta-1b) [Package insert]. (2008).Montville, NJ: Bayer Healthcare Pharmaceuticals.
3. Copaxone® (glatiramer acetate) [Package insert]. (2009). Kansas City, MO: Teva Neuroscience, Inc.
4. Extavia® (interferon beta-1b) [Package insert]. (2009). East Hanover, NJ: Novartis Pharmaceuticals Corporation.
5. Lim, S. T., & Constantinescu, C. S. (2010). Current and future disease-modifying therapies in multiple sclerosis. International Journal of Clinical Practice, 64, 637-650.
6. Novantrone® (mitoxantrone) [Package insert]. (2008). Rockland, MA: EMD Serono, Inc.
7. Pittock, S. J., Mayr, W. T., & McClelland, R. L. (2004). Change in MS-related disability in a population-based cohort: A 10-year follow-up study. Neurology, 62(1), 51-59.
8. Polman, C. H., Reingold, S. C., Edan G., Filippi, M., Hartung, H. P., Kappos, L., et al. (2005). Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Annals of Neurology, 58, 840-846.
9. Rebif® (interferon beta-1a) [Package insert]. (2009). Rockland, MA: EMD Serono, Inc.
10. Tysabri® (natalizumab) [Package insert]. (2008). Cambridge, MA: Biogen Idec, Inc.